Teva’s Choice: Rapid Earnings Growth or Investment in R&D

CEO Erez Vigodman gave a U.S. health-care conference a look at the mistakes the drugmaker made over the years and his view to the future.

comments Print
What does Erez Vigodman, the CEO of Teva Pharmaceutical, prefer? A major acquisition of a synergistic company that will boost earnings per share to the delight of the capital markets? Or does he want to...